

Antimicrobial Agent	Disc Code	Potency	Test Cultures (zone diameters in mm)		
			Resistant	Intermediate	Susceptible
<b>Amikacin</b> <i>Enterobacteriaceae</i> <sup>6</sup> , <i>P. aeruginosa</i> , <i>Acinetobacter</i> spp., and <i>Staphylococcus</i> spp.	AK	30 µg	≤14	15-16	≥17
<b>Amoxicillin - Clavulanic Acid</b> <i>Enterobacteriaceae</i> <sup>6</sup> <i>Staphylococcus</i> spp. <sup>1,2</sup> <i>Haemophilus</i> spp. <sup>1,3</sup>	AMC	20/10 µg	≤13 ≤19 ≤19	14-17 — —	≥18 ≥20 ≥20
<b>Ampicillin</b> <sup>2,4</sup> <i>Enterobacteriaceae</i> and <i>Vibrio cholerae</i> <sup>6</sup> <i>Staphylococcus</i> spp. <sup>1,2</sup> <i>Enterococcus</i> spp. <sup>1,3,5,6,8</sup> <i>Haemophilus</i> spp. <sup>7</sup> <i>Streptococcus</i> spp. β-Hemolytic Group <sup>4,8</sup>	AMP	10 µg	≤13 ≤28 ≤16 ≤18 —	14-16 — — 19-21 —	≥17 ≥29 ≥17 ≥22 ≥24
<b>Ampicillin - Sulbactam</b> <i>Enterobacteriaceae</i> <sup>6</sup> , <i>Acinetobacter</i> spp., and <i>Staphylococcus</i> spp. <i>Haemophilus</i> spp. <sup>1,3</sup>	SAM	10/10 µg	≤11 ≤19	12-14 —	≥15 ≥20
<b>Azithromycin</b> <i>Staphylococcus</i> spp., <i>Streptococcus</i> spp. Viridans Group <sup>1</sup> , β-Hemolytic Group, and <i>S. pneumoniae</i> <sup>6</sup> <i>Neisseria meningitidis</i> <sup>1,3</sup> <i>Haemophilus</i> spp. <sup>1</sup>	AZM	15 µg	≤13 — —	14-17 — —	≥18 ≥20 ≥12
<b>Aztreonam</b> <i>Enterobacteriaceae</i> <sup>6</sup> <i>P. aeruginosa</i> <i>Haemophilus</i> spp. <sup>1</sup>	ATM	30 µg	≤17 ≤15 —	18-20 16-21 —	≤21 ≥22 ≥26
<b>Carbenicillin</b> <i>Enterobacteriaceae</i> <i>Pseudomonas aeruginosa</i> <sup>6</sup>	CAR	100 µg	≤19 ≤13	20-22 14-16	≥23 ≥17
<b>Cefaclor</b> <i>Enterobacteriaceae</i> and <i>Staphylococcus</i> spp. <i>Haemophilus</i> spp. <sup>7</sup>	CEC	30 µg	≤14 ≤16	15-17 17-19	≥18 ≥20
<b>Cefamandole</b> <i>Enterobacteriaceae</i> <sup>2,5</sup> and <i>Staphylococcus</i> spp.	MA	30 µg	≤14	15-17	≥18
<b>Cefazolin</b> <sup>9</sup> <i>Staphylococcus</i> spp. <i>Enterobacteriaceae</i>	KZ	30 µg	≤14 ≤19	15-17 20-22	≥18 ≥23
<b>Cefepime</b> <i>Enterobacteriaceae</i> <sup>6</sup> , <i>P. aeruginosa</i> , <i>Acinetobacter</i> spp., and <i>Staphylococcus</i> spp. <i>Haemophilus</i> spp. <sup>1</sup> <i>Neisseria gonorrhoeae</i> <sup>4</sup> <i>Streptococcus</i> spp. β-Hemolytic Group <sup>4,8</sup> <i>Streptococcus</i> spp. Viridans Group <sup>6</sup>	FEP	30 µg	≤14 — — — ≤21	15-17 — — — 22-23	≥18 ≥26 ≥31 ≥24 ≥24
<b>Cefixime</b> <i>Enterobacteriaceae</i> <sup>2,11</sup> <i>Haemophilus</i> spp. <sup>1</sup> <i>Neisseria gonorrhoeae</i> <sup>4</sup>	CFM	5 µg	≤15 — —	16-18 — —	≥19 ≥21 ≥31
<b>Cefonicid</b> <i>Enterobacteriaceae</i> <sup>2,5</sup> and <i>Staphylococcus</i> spp. <i>Haemophilus</i> spp. <sup>7</sup>	CID	30 µg	≤14 ≤16	15-17 17-19	≥18 ≥20
<b>Cefoperazone</b> <i>Enterobacteriaceae</i> <sup>2,1</sup> , <i>P. aeruginosa</i> and <i>Staphylococcus</i> spp.	CFP	75 µg	≤15	16-20	≥21
<b>Cefotaxime</b> <i>Enterobacteriaceae</i> <sup>2,5,12</sup> <i>P. aeruginosa</i> , <i>Acinetobacter</i> spp., and <i>Staphylococcus</i> spp. <i>Haemophilus</i> spp. <sup>1</sup> <i>Neisseria meningitidis</i> <sup>1,3</sup> <i>Neisseria gonorrhoeae</i> <sup>4</sup> <i>Streptococcus</i> spp. β-Hemolytic Group <sup>4,8</sup> <i>Streptococcus</i> spp. Viridans Group <sup>6</sup>	CTX	30 µg	≤22 ≤14 — — — — ≤25	23-25 15-22 — — — — 26-27	≥26 ≥23 ≥26 ≥34 ≥31 ≥24 ≥28
<b>Cefotetan</b> <i>Enterobacteriaceae</i> <sup>2,4</sup> and <i>Staphylococcus</i> spp. <i>Neisseria gonorrhoeae</i> <sup>2</sup>	CTT	30 µg	≤12 ≤19	13-15 20-25	≥16 ≥26
<b>Cefoxitin</b> <i>Enterobacteriaceae</i> <i>S. aureus</i> and <i>S. lugdunensis</i> <sup>1,3,5</sup> Coagulase-negative staphylococci <sup>1,3,5</sup> (except <i>S. lug.</i> ) <i>Neisseria gonorrhoeae</i> <sup>2</sup>	FOX	30 µg	≤14 ≤21 ≤24 ≤23	15-17 — — 24-27	≥18 ≥22 ≥25 ≥28
<b>Cefpodoxime</b> <i>Enterobacteriaceae</i> <sup>2,5,11</sup> and <i>Staphylococcus</i> spp. <i>Haemophilus</i> spp. <sup>1</sup> <i>Neisseria gonorrhoeae</i> <sup>4</sup>	CPD	10 µg	≤17 — —	18-20 — —	≥21 ≥21 ≥29
<b>Cefprozil</b> <i>Enterobacteriaceae</i> <sup>2,1</sup> , <i>Staphylococcus</i> spp., and <i>Haemophilus</i> spp. <sup>7</sup>	CPR	30 µg	≤14	15-17	≥18
<b>Ceftazidime</b> <i>Enterobacteriaceae</i> <sup>2,1</sup> <i>P. aeruginosa</i> , <i>Acinetobacter</i> spp., and <i>Staphylococcus</i> spp. <i>B. cepacia</i> <i>Haemophilus</i> spp. <sup>1</sup> <i>Neisseria gonorrhoeae</i> <sup>4</sup>	CAZ	30 µg	≤17 ≤14 ≤17 — —	18-20 15-17 18-20 — —	≥21 ≥18 ≥21 ≥26 ≥31
<b>Ceftiozone</b> <i>Enterobacteriaceae</i> <sup>2,1</sup> , <i>P. aeruginosa</i> and <i>Staphylococcus</i> spp. <i>Haemophilus</i> spp. <sup>1</sup> <i>Neisseria gonorrhoeae</i> <sup>4</sup>	ZOX	30 µg	≤21 ≤14 — —	22-24 15-19 — —	≥25 ≥20 ≥26 ≥38
<b>Ceftaroline</b> <i>Haemophilus</i> spp. <i>Streptococcus</i> spp. β-Hemolytic Group, <i>S. Pneumoniae</i> <i>Enterobacteriaceae</i> <i>Staphylococcus</i> spp			— — ≤19 ≤20	— — 20-22 21-23	≥30 ≥26 ≥23 ≥24
<b>Ceftriaxone</b> <i>Enterobacteriaceae</i> <sup>2,1,13</sup> <i>P. aeruginosa</i> , <i>Acinetobacter</i> spp., and <i>Staphylococcus</i> spp. <i>Haemophilus</i> spp. <sup>1</sup> <i>Neisseria meningitidis</i> <sup>1,3</sup> <i>Neisseria gonorrhoeae</i> <sup>4</sup> <i>Streptococcus</i> spp. β-Hemolytic Group <sup>4,8</sup> <i>Streptococcus</i> spp. Viridans Group <sup>6</sup>	CRO	30 µg	≤19 ≤13 — — — — ≤24	20-22 14-20 — — — — 25-26	≥23 ≥21 ≥26 ≥34 ≥35 ≥24 ≥27
<b>Cefuroxime (parenteral)</b> <i>Enterobacteriaceae</i> <sup>2,5</sup> , and <i>Staphylococcus</i> spp. <i>Haemophilus</i> spp. <sup>7</sup> <i>Neisseria gonorrhoeae</i> <sup>4</sup>	CXM	30 µg	≤14 ≤16 ≤25	15-17 17-19 26-30	≥18 ≥20 ≥31
<b>Cephalothin</b> <i>Enterobacteriaceae</i> <sup>2,5,10</sup> and <i>Staphylococcus</i> spp.	KF	30 µg	≤14	15-17	≥18
<b>Chloramphenicol</b> <sup>8</sup> <i>Enterobacteriaceae</i> , <i>Staphylococcus</i> spp., <i>Enterococcus</i> spp., and <i>Vibrio cholerae</i> <sup>6</sup> <i>Haemophilus</i> spp. <i>Neisseria meningitidis</i> <i>Streptococcus pneumoniae</i> <sup>4</sup> <i>Streptococcus</i> spp. Viridans Group <sup>1</sup> and β-Hemolytic Group	C	30 µg	≤12 ≤25 ≤19 ≤20 ≤17	13-17 26-28 20-25 — 18-20	≥18 ≥29 ≥26 ≥21 ≥21
<b>Ciprofloxacin</b> <i>P. aeruginosa</i> , <i>Acinetobacter</i> spp., <i>Staphylococcus</i> spp. <sup>1</sup> , and <i>Enterococcus</i> spp. <sup>2</sup> <i>Haemophilus</i> spp. <sup>1</sup> <i>Neisseria meningitidis</i> <sup>1,3</sup> <i>Neisseria gonorrhoeae</i> <sup>4</sup> <i>Enterobacteriaceae</i> <sup>6</sup>	CIP	5 µg	≤15 — ≤32 ≤27 ≤20	16-20 — 33-34 28-40 21-30	≥21 ≥21 ≥35 ≥41 ≥31
<b>Clarithromycin</b> <i>Staphylococcus</i> spp. <i>Haemophilus</i> spp. <i>Streptococcus</i> spp. <sup>2</sup> Viridans Group <sup>1</sup> , β-Hemolytic Group, and <i>S. pneumoniae</i>	CLR	15 µg	≤13 ≤10 ≤16	14-17 11-12 17-20	≥18 ≥13 ≥21
<b>Clindamycin</b> <i>Staphylococcus</i> spp. <sup>1</sup> <i>Streptococcus</i> spp. Viridans Group <sup>1</sup> , β-Hemolytic Group, and <i>S. pneumoniae</i>	DA	2 µg	≤14 ≤15	15-20 16-18	≥21 ≥19
<b>Colistin</b> <sup>8</sup> <i>Pseudomonas aeruginosa</i> <sup>6</sup>	CT	10 µg	≤10	—	≥11

<b>Doripenem</b> <i>P.aeruginosa</i> <i>Haemophilus</i> spp.	DOR	10 µg	≤15 —	16-18 —	≥19 ≥16
<b>Doxycycline</b> <i>Enterobacteriaceae</i> , <i>Acinetobacter</i> spp., <i>Staphylococcus</i> spp. and <i>Enterococcus</i> spp. <i>S.pneumoniae</i>	DO	30 µg	≤10 ≤9 ≤12 ≤24	11-13 10-12 13-15 25-27	≥14 ≥13 ≥16 ≥28
<b>Ertapenem</b> <i>Enterobacteriaceae</i> <sup>1</sup> <i>Haemophilus</i> spp. <sup>Δ</sup> <i>Staphylococcus</i> spp. <sup>Ω</sup>	ETP	10 µg	≤18 — ≤15	19-21 — 16-18	≥22 ≥19 ≥19

Antimicrobial Agent	Disc Code	Potency	Test Cultures (zone diameters in mm)		
			Resistant	Intermediate	Susceptible
<b>Erythromycin<sup>9</sup></b> <i>Staphylococcus</i> spp. <sup>1</sup> and <i>Enterococcus</i> spp. <i>Streptococcus</i> spp. <sup>2</sup> Viridans Group <sup>3</sup> , β-Hemolytic Group, and <i>S. pneumoniae</i>	E	15 µg	≤13	14-22	≥23
<b>Gentamicin</b> <i>Enterobacteriaceae</i> , <i>P. aeruginosa</i> , <i>Acinetobacter</i> spp., and <i>Staphylococcus</i> spp.	CN	10 µg	≤12	13-14	≥15
<b>Imipenem</b> <i>Enterobacteriaceae</i> , <i>P. aeruginosa</i> , <i>Acinetobacter</i> spp., and <i>Staphylococcus</i> spp. <sup>2</sup> <i>Haemophilus</i> spp. <sup>3</sup>	IPM	10 µg	≤13	14-15	≥16
<b>Kanamycin</b> <i>Enterobacteriaceae</i> <sup>6</sup> and <i>Staphylococcus</i> spp.	K	30 µg	≤13	14-17	≥18
<b>Levofloxacin</b> <i>Enterobacteriaceae</i> <sup>4</sup> , <i>P. aeruginosa</i> , <i>S. maltophilia</i> , <i>Acinetobacter</i> spp., <i>Enterococcus</i> spp. <sup>5</sup> , <i>Streptococcus</i> spp. Viridans Group <sup>3</sup> , β-Hemolytic Group, and <i>S. pneumoniae</i> <i>Staphylococcus</i> spp. <sup>7</sup> <i>Haemophilus</i> spp. <sup>8</sup>	LEV	5 µg	≤13	14-16	≥17
<b>Linezolid</b> <i>Staphylococcus</i> spp. <i>Streptococcus</i> spp. <sup>1</sup> Viridans Group <sup>3</sup> , β-Hemolytic Group and <i>S. pneumoniae</i> <i>Enterococcus</i> spp.	LZD	30 µg	≤20	—	≥21
<b>Lomefloxacin</b> <i>Enterobacteriaceae</i> <sup>10</sup> , <i>P. aeruginosa</i> <sup>2</sup> and <i>Staphylococcus</i> spp. <sup>11</sup> <i>Haemophilus</i> spp. <sup>3</sup> <i>Neisseria gonorrhoeae</i>	LOM	10 µg	≤18	19-21	≥22
<b>Mecillinam</b> <i>Enterobacteriaceae</i> <sup>12</sup>	MEL	10 µg	≤26	27-37	≥38
<b>Meropenem</b> <i>Enterobacteriaceae</i> <sup>6</sup> <i>P. aeruginosa</i> , <i>Acinetobacter</i> spp., and <i>Staphylococcus</i> spp. <sup>2</sup> <i>B. cepacia</i> <i>Neisseria meningitidis</i> <sup>3</sup> <i>Haemophilus</i> spp. <sup>4</sup>	MEM	10 µg	≤19	20-22	≥23
<b>Mezlocillin</b> <i>Enterobacteriaceae</i> and <i>Acinetobacter</i> spp. <i>Pseudomonas aeruginosa</i> <sup>13</sup>	MEZ	75 µg	≤17	18-20	≥21
<b>Minocycline</b> <i>Enterobacteriaceae</i> , <i>P. aeruginosa</i> and <i>Acinetobacter</i> spp. <i>Neisseria meningitidis</i> <sup>4</sup> <i>S. maltophilia</i> , <i>B. cepacia</i> , <i>Staphylococcus</i> spp., and <i>Enterococcus</i> spp.	MH	30 µg	≤12	13-15	≥16
<b>Moxifloxacin</b> <i>Staphylococcus</i> spp. <sup>7</sup> <i>Streptococcus pneumoniae</i> <i>Haemophilus</i> spp. <sup>8</sup>	MFX	5 µg	≤20	21-23	≥24
<b>Nafcillin</b> <i>Staphylococcus aureus</i>	NF	1 µg	≤10	11-12	≥13
<b>Nalidixic Acid</b> <i>Enterobacteriaceae</i> <sup>4</sup> <i>Neisseria meningitidis</i>	NA	30 µg	≤13	14-18	≥19
<b>Netilmicin</b> <i>Enterobacteriaceae</i> , <i>P. aeruginosa</i> and <i>Staphylococcus</i> spp.	NET	30 µg	≤25	—	≥26
<b>Nitrofurantoin<sup>2</sup></b> <i>Enterobacteriaceae</i> , <i>Staphylococcus</i> spp., and <i>Enterococcus</i> spp.	F	300 µg	≤12	13-14	≥15
<b>Norfloxacin<sup>2</sup></b> <i>Enterobacteriaceae</i> <sup>6</sup> <i>P. aeruginosa</i> , <i>Staphylococcus</i> spp. <sup>7</sup> and <i>Enterococcus</i> spp.	NOR	10 µg	≤14	15-16	≥17
<b>Olofloxacin</b> <i>Enterobacteriaceae</i> <sup>14</sup> , <i>P. aeruginosa</i> <sup>2</sup> , and <i>Streptococcus</i> spp. Viridans Group <sup>3</sup> , β-Hemolytic Group, and <i>S. pneumoniae</i> <i>Staphylococcus</i> spp. <sup>7</sup> <i>Haemophilus</i> spp. <sup>8</sup> <i>Neisseria gonorrhoeae</i>	OFX	5 µg	≤12	13-15	≥16
<b>Oxacillin</b> <i>S. aureus</i> <sup>15</sup> <i>S. pneumoniae</i> (for penicillin susceptibility) <sup>16</sup>	OX	1 µg	≤14	15-17	≥18
<b>Penicillin</b> <i>Staphylococcus</i> spp. <sup>17,18</sup> <i>Enterococcus</i> spp. <sup>19,20,21</sup> <i>Neisseria gonorrhoeae</i> <sup>22</sup> <i>Streptococcus</i> spp. β-Hemolytic Group <sup>23</sup>	P	10 U	≤24	25-30	≥31
<b>Piperacillin</b> <i>Enterobacteriaceae</i> and <i>Acinetobacter</i> spp. <i>Pseudomonas aeruginosa</i> <sup>13</sup>	PRL	100 µg	≤10	11-12	≥13
<b>Piperacillin - Tazobactam</b> <i>Enterobacteriaceae</i> and <i>Acinetobacter</i> spp. <i>Pseudomonas aeruginosa</i> <sup>2</sup> <i>Staphylococcus</i> spp. <sup>1</sup> <i>Haemophilus</i> spp. <sup>11</sup>	TZP	100/10 µg	≤17	18-20	≥21
<b>Polymyxin B<sup>24</sup></b> <i>Pseudomonas aeruginosa</i> <sup>25</sup>	PB	300 U	≤14	15-20	≥21
<b>Quinupristin – Dalopristin</b> <i>Staphylococcus</i> spp., <i>Enterococcus</i> spp., and <i>Streptococcus</i> spp. Viridans Group <sup>3</sup> , β-Hemolytic Group, and <i>S. pneumoniae</i>	QD	15 µg	≤11	—	≥12
<b>Rifampin<sup>26</sup></b> <i>Staphylococcus</i> spp., <i>Enterococcus</i> spp., and <i>Haemophilus</i> spp. <i>Neisseria meningitidis</i> <i>Streptococcus pneumoniae</i>	RD	5 µg	≤15	16-18	≥19
<b>Spectinomycin</b> <i>Neisseria gonorrhoeae</i> <sup>27</sup>	SH	100 µg	≤16	17-19	≥20
<b>Streptomycin</b> <i>Enterobacteriaceae</i> <sup>28</sup>	S	10 µg	≤19	20-24	≥25
<b>Sulfisoxazole<sup>29</sup></b> <i>Enterobacteriaceae</i> <sup>30</sup> , <i>Staphylococcus</i> spp. <sup>31</sup> and <i>Vibrio cholerae</i>	SFX	300 µg	≤16	17-18	≥19
<b>Teicoplanin</b> <i>Staphylococcus</i> spp. and <i>Enterococcus</i> spp.	TEC	30 µg	≤11	12-14	≥15
<b>Tellithromycin</b> <i>Staphylococcus</i> spp. <i>Haemophilus</i> spp. <i>Streptococcus pneumoniae</i>	TEL	15 µg	≤12	13-16	≥17
<b>Tetracycline</b> <i>Enterobacteriaceae</i> and <i>Acinetobacter</i> spp. <i>Staphylococcus</i> spp., <i>Enterococcus</i> spp., and <i>Vibrio cholerae</i> <i>Haemophilus</i> spp. <i>Neisseria gonorrhoeae</i> <i>Streptococcus</i> spp. Viridans Group, β-Hemolytic Group <i>S. pneumoniae</i>	TE	30 µg	≤18	19-21	≥22
<b>Ticarcillin</b> <i>Enterobacteriaceae</i> and <i>Acinetobacter</i> spp. <i>Pseudomonas aeruginosa</i> <sup>13</sup>	TIC	75 µg	≤11	12-14	≥15
<b>Ticarcillin - Clavulanic Acid</b> <i>Enterobacteriaceae</i> and <i>Acinetobacter</i> spp. <i>Pseudomonas aeruginosa</i> <sup>2</sup> <i>Staphylococcus</i> spp. <sup>1</sup>	TIM	75/10 µg	≤14	15-19	≥20
<b>Tigecycline</b>	TGC	15µg	≤15	16-23	≥24
<b>Tobramycin</b> <i>Enterobacteriaceae</i> <sup>6</sup> , <i>P. aeruginosa</i> , <i>Acinetobacter</i> spp., and <i>Staphylococcus</i> spp.	TOB	10 µg	≤17	18-20	≥21
<b>Trimethoprim<sup>32</sup></b> <i>Enterobacteriaceae</i> and <i>Staphylococcus</i> spp.	W	5 µg	≤11	12-14	≥15
<b>Trimethoprim-Sulfamethoxazole</b> <i>Enterobacteriaceae</i> , <i>Acinetobacter</i> spp., <i>Staphylococcus</i> spp., <i>Haemophilus</i> spp., <i>Vibrio cholerae</i> , <i>B. cepacia</i> , and <i>S. maltophilia</i> <i>Neisseria meningitidis</i> <i>Streptococcus pneumoniae</i>	SXT	1.25/23.75 µg	≤10	11-15	≥16
<b>Vancomycin</b> <i>Enterococcus</i> spp. <sup>33</sup> <i>Streptococcus</i> spp. Viridans Group, β-Hemolytic Group, and <i>S. pneumoniae</i>	VA	30 µg	≤14	15-16	≥17



The FDA susceptibility test interpretive criteria are derived from the antibacterial drug product's labeling at the time of the original new drug application (NDA) approval or a subsequent update.

Antimicrobial Agent	Disc Code	Potency	Test Cultures (zone diameters in mm)			Data Source
			Resistant	Intermediate	Susceptible	
<b>Aminikacin</b>	AK	30 µg	≤14	15-16	≥17	DailyMed: Bristol-Myers Squibb Co., 01/2001
<b>Amoxicillin - Clavulanic Acid</b> Staphylococcus spp. & Haemophilus influenzae Other organisms exc. Streptococcus pneumoniae & Neisseria gonorrhoeae	AMC	20/10 µg	≤19	-	≥20	DailyMed: Sandoz Inc., 09/2009
<b>Ampicillin - Sulbactam</b> Gram-negative & Staphylococcus spp. Haemophilus influenzae	SAM	10/10 µg	≤11	12-13	≥14	DailyMed: Baxter Healthcare Corp., 05/2009
<b>Azithromycin</b> Haemophilus spp. Staphylococcus aureus Streptococcus spp. incl. Streptococcus pneumoniae	AZM	15 µg	≤13	14-17	≥18	DailyMed: Pfizer Inc., 01/2009
<b>Aztreonam</b> Aerobic organisms other than Haemophilus influenzae Haemophilus influenzae	ATM	30 µg	≤15	16-21	≥22	DailyMed: Bristol-Meyers Squibb, 07/2007
<b>Bacitracin</b> Staphylococcus aureus	B	10 U	-	-	>13	DailyMed: Pharmacia & Upjohn, 09/2006
<b>Carbenicillin</b> Enterobacter spp. Pseudomonas spp.	CAR	100 µg	≤17	18-22	≥23	DailyMed: Roesig, 05/2007
<b>Cefaclor</b> Organisms other than Haemophilus spp. & Streptococcus spp.	CEC	30 µg	≤14	15-17	≥18	DailyMed: Ranbaxy Pharma. Inc., 05/2007
<b>Cefazolin</b> Organisms other than Haemophilus spp. & Strep pneumoniae	FEP	30 µg	≤14	15-17	≥18	DailyMed: Baxter Healthcare Corp., 01/2010
<b>Cefepime</b> Organisms other than Haemophilus spp., N. gonorrhoeae, Streptococcus	CFM	5 µg	-	-	≥21	Lupin Pharmaceuticals, Inc., 10/2008
<b>Cefepime</b> Organisms other than Haemophilus spp., N. gonorrhoeae, Strep spp.	CFP	75 µg	≤15	16-20	≥21	DailyMed: Roesig (Division of Pfizer), 01/2006
<b>Cefotaxime</b> Neisseria gonorrhoeae Haemophilus spp. Streptococcus spp. other than S. pneumoniae Organisms other than Haemophilus, N. gonorrhoeae, Streptococcus	CTX	30 µg	-	-	≥21	DailyMed: Pfizer Laboratories, 12/2009
<b>Cefotaxime</b> Neisseria gonorrhoeae Organisms other than Haemophilus, N. gonorrhoeae, Streptococcus	CTT	30 µg	≤12	13-15	≥16	DailyMed: AstraZeneca Pharma, LP, 01/2004
<b>Cefotaxime</b> Neisseria gonorrhoeae Aerobic organisms other than N. gonorrhoeae	FOX	30 µg	≤23	24-27	≥28	DailyMed: Merck & Co., Inc., 10/2006
<b>Cefepodoxime</b> Enterobacteriaceae & Staphylococcus spp. Haemophilus spp. Neisseria gonorrhoeae	CPD	10 µg	≤17	18-20	≥21	DailyMed: Sandoz Inc., 09/2008
<b>Cefprozil</b> Neisseria gonorrhoeae	CPR	30 µg	≤14	15-17	≥18	DailyMed: Sandoz Inc., 01/2008
<b>Ceftazidime</b> Haemophilus spp. Neisseria gonorrhoeae Organisms other than Haemophilus spp. & N. gonorrhoeae	CAZ	30 µg	≤14	15-17	≥18	DailyMed: GlaxoSmithKline LLC, 04/2007
<b>Ceftizoxime</b> Haemophilus spp. Neisseria gonorrhoeae Organisms other than Haemophilus spp. & N. gonorrhoeae	ZOX	30 µg	-	-	≥26	DailyMed: Astellas Pharma US, Inc., No revision date.
<b>Ceftiozan</b> Haemophilus spp. Neisseria gonorrhoeae Organisms other than Haemophilus spp., N. gonorrhoeae, Strep spp.	CXM	30 µg	≤13	14-20	≥21	DailyMed: GlaxoSmithKline LLC, 12/2005
<b>Cefuroxime (parenteral)</b> Haemophilus spp. Neisseria gonorrhoeae Organisms other than Haemophilus spp. & N. gonorrhoeae	CXM	30 µg	≤14	15-22	≥23	DailyMed: GlaxoSmithKline LLC, 12/2005
<b>Cephalothin</b> Staphylococcus aureus	KF	30 µg	≤14	15-17	≥18	DailyMed: Ranbaxy Pharma. Inc., 01/2007
<b>Chloramphenicol</b> Salmonella spp. Haemophilus influenzae	C	30 µg	≤12	13-17	≥18	DailyMed: Monarch Pharma, Inc., 04/2007
<b>Ciprofloxacin</b> Enterobacteriaceae, Enterococcus faecalis, Staphylococcus spp., S. pneumoniae, S. pyogenes, & P. aeruginosa H. influenzae & H. parainfluenzae	CIP	5 µg	≤15	16-20	≥21	DailyMed: Pfizer Labs, 09/2009
<b>Clarithromycin</b> Staphylococcus spp. Streptococcus spp. including S. pneumoniae Haemophilus spp.	CLR	15 µg	≤13	14-17	≥18	DailyMed: Sandoz Inc., 09/2008
<b>Clindamycin</b> Staphylococcus spp.	DA	2 µg	≤10	11-12	≥13	DailyMed: Bedford Labs., 07/2008
<b>Doripenem</b> Enterobacteriaceae P. aeruginosa Acinetobacter baumannii Streptococcus anginosus group	DOR	10 µg	-	-	≥23	DailyMed: Ortho-McNeil-Janssen Pharm., Inc., 10/2008
<b>Doxycycline</b> Organisms other than Haemophilus spp., N. gonorrhoeae	DO	30 µg	≤12	13-15	≥16	DailyMed: Pfizer Laboratories, 02/2010
<b>Ertapenem</b> Enterobacteriaceae & Staphylococcus spp. Haemophilus spp. Streptococcus spp. including Streptococcus pneumoniae	ETP	10 µg	≤15	16-18	≥19	DailyMed: Merck Sharp & Dohme Corp., 03/2010
<b>Erythromycin</b> Organisms other than Haemophilus spp., N. gonorrhoeae, Streptococcus	E	15 µg	-	-	≥19	DailyMed: Abbott Laboratories, no revision date
<b>Gentamicin</b> Organisms other than Haemophilus spp., N. gonorrhoeae, Streptococcus	CN	10 µg	≤13	14-22	≥23	B Braun Medical Inc. 03/2007
<b>Imipenem</b> Organisms other than Haemophilus spp., N. gonorrhoeae, Streptococcus	IPM	10 µg	≤12	13-14	≥15	DailyMed: Merck & Co., Inc., 12/2007
<b>Kanamycin</b> Organisms other than Haemophilus spp., N. gonorrhoeae, Streptococcus	K	30 µg	≤13	14-15	≥16	DailyMed: Bristol-Myers Squibb Co., no revision date
<b>Levofloxacin</b> Enterobacteriaceae, E. faecalis, Staphylococcus spp. (methicillin-susceptible), P. aeruginosa, S. pneumoniae, & S. pyogenes H. influenzae & H. parainfluenzae	LEV	5 µg	≤13	14-16	≥17	DailyMed: Hikma Farmaceutica (Portugal), S.A., 07/2009
<b>Linezolid</b> Enterococcus spp. Staphylococcus spp. Streptococcus spp. including S. pneumoniae	LZD	30 µg	≤20	21-22	≥23	DailyMed: Pharmacia & Upjohn Co., 12/2009
<b>Lomefloxacin</b> Organisms other than Haemophilus spp., N. gonorrhoeae, Streptococcus	LOM	10 µg	≤18	19-21	≥22	DailyMed: G.D. Searle LLC, no revision date
<b>Meropenem</b> Enterobacteriaceae, Acinetobacter spp. & P. aeruginosa Haemophilus influenzae Staph. aureus	MEM	10 µg	≤13	14-15	≥16	DailyMed: AstraZeneca Pharm. LP, 11/2007
<b>Minocycline</b> Organisms other than Haemophilus spp., N. gonorrhoeae, Streptococcus	MH	30 µg	≤14	15-18	≥19	DailyMed: Ranbaxy Pharma. Inc., 04/2007
<b>Moxifloxacin</b> Enterobacteriaceae & Staph. aureus (methicillin-susceptible) H. influenzae & H. parainfluenzae Streptococcus spp. including S. pneumoniae & E. faecalis	MFX	5 µg	≤15	16-18	≥19	DailyMed: Shering Plough Corp., 10/2008
<b>Nalidixic Acid</b> Organisms other than Haemophilus spp., N. gonorrhoeae, Streptococcus	NA	30 µg	≤10	11-12	≥13	DailyMed: Santol-Aventis U.S. LLC, 09/2008
<b>Neomycin</b> Organisms other than Haemophilus spp., N. gonorrhoeae, Streptococcus	N	30 µg	≤13	14-15	≥16	DailyMed: TEVA pharma USA 03/2007
<b>Nitrofurantoin</b> Organisms other than Haemophilus spp., N. gonorrhoeae, Streptococcus	F	300 µg	≤14	15-16	≥17	DailyMed: Procter & Gamble Pharma., 01/2009
<b>Norfloxacin</b> Organisms other than Haemophilus spp., N. gonorrhoeae, Streptococcus	NOR	10 µg	≤12	13-16	≥17	DailyMed: Merck Sharp & Dohme Corp., 02/2010
<b>Ofloxacin</b> Enterobacteriaceae, P. aeruginosa, & S.aureus (methicillin-susceptible) Haemophilus influenzae Neisseria gonorrhoeae Streptococcus pneumoniae & Streptococcus pyogenes	OFX	5 µg	≤12	13-15	≥16	DailyMed: Teva Pharma. USA, 01/2008
<b>Oxacillin</b> Staphylococcus aureus Coccalase-negative Staphylococcus spp.	OX	1 µg	≤10	11-12	≥13	DailyMed: Baxter Healthcare Corp., 02/2007
<b>Penicillin</b> Staphylococcus spp. Neisseria gonorrhoeae Beta-hemolytic streptococci	P	10 U	≤28	-	≥29	DailyMed: Baxter Healthcare Corp., 02/2008
<b>Piperacillin</b> Enterobacteriaceae & Acinetobacter spp. Pseudomonas aeruginosa Enterococcus faecalis Haemophilus spp.	PRL	100 µg	≤17	18-20	≥21	DailyMed: Wyeth Pharma. Inc., 03/2007
<b>Piperacillin - Tazobactam</b> Enterobacteriaceae & Acinetobacter baumannii Pseudomonas aeruginosa Staphylococcus aureus	TZP	100/10 µg	≤17	18-20	≥21	DailyMed: Wyeth Pharma. Inc., 09/2009
<b>Polymyxin B</b> Organisms other than Haemophilus spp., N. gonorrhoeae, Streptococcus	PB	300 U	-	-	>11	DailyMed: Bedford Laboratories, 02/2004
<b>Quinupristin - Dalopristin</b> Enterococcus faecium, Staphylococcus spp., & Streptococcus spp. (excluding S. pneumoniae)	QD	15 µg	≤15	16-18	≥19	DSM Pharma, Inc., 07/2003
<b>Rifampin</b> Organisms other than Haemophilus spp., N. gonorrhoeae, Streptococcus	RD	5 µg	≤16	17-19	≥20	DailyMed: Lannett Company, Inc., 10/2007
<b>Streptomycin</b> Organisms other than Haemophilus spp., N. gonorrhoeae, Streptococcus	S	10 µg	≤10	11-12	≥13	Roesig (Division of Pfizer), 08/2006
<b>Sulfisoxazole</b> Organisms other than Haemophilus spp., N. gonorrhoeae, Streptococcus	SFX	300 µg	≤12	13-16	≥17	DailyMed: Roche Laboratories Inc., 11/1997
<b>Telithromycin</b> Streptococcus pneumoniae Haemophilus influenzae	TEL	15 µg	≤15	16-18	≥19	DailyMed: Santol-Aventis U.S. LLC, 06/2009
<b>Tetracycline</b> Organisms other than Haemophilus spp., N. gonorrhoeae, Streptococcus	TE	30 µg	-	-	≥19	DailyMed: Blenheim Pharmaceut. Inc., 06/2009
<b>Ticarclillin</b> Pseudomonas aeruginosa & Enterobacteriaceae	TIC	75 µg	≤11	12-14	≥15	GlaxoSmithKline, 09/2002
<b>Ticarclillin - Clavulanic Acid</b> Staphylococcus spp. Enterobacteriaceae Pseudomonas aeruginosa	TIM	75/10 µg	≤22	-	≥23	DailyMed: GlaxoSmithKline LLC, 02/2009
<b>Tigecycline</b> Enterobacteriaceae Staphylococcus aureus, Streptococcus spp. (including S. pneumoniae), Enterococcus faecalis, & Haemophilus influenzae	TGC	15 µg	≤14	15-18	≥19	DailyMed: Wyeth Pharmaceuticals Inc., 07/2010
<b>Tobramycin</b> Organisms other than Haemophilus spp., N. gonorrhoeae, Streptococcus	TOB	10 µg	≤12	13-14	≥15	DailyMed: Akorn-Strides, LLC, 08/2007
<b>Trimethoprim</b> Enterobacteriaceae & Staphylococcus spp.	W	5 µg	≤10	11-15	≥16	DailyMed: Watson Laboratories, Inc., 06/2006
<b>Trimethoprim-Sulfamethoxazole</b> Enterobacteriaceae & Haemophilus influenzae Streptococcus pneumoniae	SXT	1.25 / 23.75 µg	≤10	11-15	≥16	DailyMed: Blenheim Pharmaceut. Inc., 08/2008
<b>Vancomycin</b> Staphylococcus spp. (not including S. pneumoniae) Enterococcus spp.	VA	30 µg	-	-	≥15	DailyMed: Baxter Healthcare Corp., 02/2009

ATCC Licensed Derivative

\*Look for the ATCC Licensed Derivative Emblem® for products derived from ATCC® cultures. †The ATCC Licensed Derivative Emblem®, the ATCC Licensed Derivative word mark®, and the ATCC catalog marks are trademarks of ATCC. Oxoid Ltd is licensed to use these trademarks and sell products derived from ATCC® cultures.



Oxoid Ltd, Wade Road, Basingstoke, Hants RG24 8PW, UK  
Tel: +44 (0)1256 841144 Fax: +44 (0)1256 463388 oxoid@thermofisher.com www.oxid.com

